The mechanism of bleomycin in inducing haemangioma regression

South African Medical Journal

Volumn 98, Issue 7, 2008, Pages 538-539

  Mabeta, Peace ^a   Davis, P F ^b  

^a UNIVERSITY OF PRETORIA   (South Africa)

^b UNIVERSITY OF OTAGO   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

BLEOMYCIN;

ANTIANGIOGENIC ACTIVITY; CONTROLLED STUDY; DRUG MECHANISM; HEMANGIOMA; HUMAN; HUMAN TISSUE; LETTER; MICROVASCULATURE; REMISSION; TISSUE CULTURE;

ANTIBIOTICS, ANTINEOPLASTIC; BLEOMYCIN; CHILD; DISEASE PROGRESSION; HEMANGIOMA; HUMANS; NEOVASCULARIZATION, PATHOLOGIC; REMISSION INDUCTION; TREATMENT OUTCOME;

EID: 48749115036     PISSN: 02569574     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Letter

References (7)

1. Tan ST, Wallis RA, He Y, Davis PF. Mast cells and hemangioma. Plast Reconstr Surg 2004; 113: 999-1011.
2. Tan ST, Hasan Q, Velickovic M, et al. A novel in vitro human model of haemangioma. Mod Pathol 2000; 13: 92-99.
3. Sterescu AE, Rousseau-Harsany E, Farrell C, et al. The potential efficacy of ω-3 fatty acids as anti-angiogenic agents in benign vascular tumors of infancy. Med Hypoth 2005; 66: 1121-1124.
4. Kullendorf CM. Efficacy of bleomycin treatment for symptomatic hemangiomas in children Pediatr Surg Int 1997; 11526-328.
5. Sarihan H, Mocan H, Yildiz K, Abes M, Akyazici R. A new treatment with bleomycin for complicated cutaneous hemangiomas in children. Eur J Pediatr Surg 1997; 7: 158-162.
6. Muir T, Kirsten M, Fourie P, et al. Intralesional bleomycin injection (IBI) treatment for haemangiomas and congenital vascular malformations. Pediatr Surg Int 2004; 19: 766-773.
7. Pienaar C, Graham R, Geldenhuys S, Hudson DA. Intralesional bleomycin for the treatment of hemangiomas. Plast Reconstr Surg 2006; 117: 221-226.